NCT07183657

Brief Summary

Comprehensive assessment and interventions to promote adherence to inhaled therapy in patients with bronchial asthma and chronic obstructive pulmonary disease involving health care professionals caring for these patients in different settings and using the Five Steps Assessment tool and artificial intelligence methods and tools.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
1,000

participants targeted

Target at P75+ for not_applicable

Timeline
33mo left

Started Jun 2025

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress26%
Jun 2025Dec 2028

Study Start

First participant enrolled

June 3, 2025

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

July 23, 2025

Completed
2 months until next milestone

First Posted

Study publicly available on registry

September 19, 2025

Completed
1.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2026

Expected
2 years until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2028

Last Updated

September 30, 2025

Status Verified

July 1, 2025

Enrollment Period

1.6 years

First QC Date

July 23, 2025

Last Update Submit

September 25, 2025

Conditions

Keywords

Chronic Obstructive Pulmonary Disease (COPD)InterventionMobile ApplicationBronchial asthmaAdherenceInhaled therapy

Outcome Measures

Primary Outcomes (4)

  • Adherence to inhaled treatment measured by Five Steps Assessment (FSA).

    Assessment of adherence to inhaled treatment measured by patients' behavior towards inhaled treatment and a number of mistakes in inhalation technique.

    Assessment of adherence to inhaled treatment within 12 months.

  • Adherence to inhaled treatment measured by the Medication Adherence Report Scale (MARS).

    Assessment of adherence to inhaled treatment measured by patients' behavior towards inhaled treatment and a number of mistakes in inhalation technique.

    Assessment of adherence to inhaled treatment within 12 months.

  • Critical knowledge measured by our own questionnaire in healthcare professionals caring for patients with COPD and bronchial asthma.

    Assessment of Critical knowledge by questions on correct usage of particular inhalation systems related to inhalation techniques in healthcare professionals caring for patients with COPD and bronchial asthma.

    Critical knowledge related to inhalation techniques in healthcare professionals caring for patients with COPD and bronchial asthma within 12 months

  • Critical skills related to inhalation techniques measured by FSA in healthcare professionals caring for patients with COPD and bronchial asthma.

    Assessment of critical skills measured by a number of mistakes in inhalation technique in particular inhalation systems related to inhalation techniques in healthcare professionals caring for patients with COPD and bronchial asthma.

    Critical skills related to inhalation techniques in healthcare professionals caring for patients with COPD and bronchial asthma within 12 months.

Secondary Outcomes (1)

  • Assessment of clinical (e.g. CAT in patients with COPD) and laboratory (e.g. white blood cell count) biomarkers potentially indicating the stability of COPD and bronchial asthma in a subgroup of patients.

    Assessment of clinical and laboratory biomarkers potentially indicating the stability of COPD and bronchial asthma within 12 months.

Study Arms (1)

All project participants

OTHER

Education of inhalation technique

Other: Education in inhalation technique

Interventions

Education in inhalation technique

All project participants

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • signed informed consent,
  • age ≥ 18 years,
  • previously diagnosed BA/COPD meeting GOLD 2024 and GINA 2024 diagnostic criteria,
  • ability to cooperate,
  • at least 8 weeks without exacerbation,
  • use of a particular inhaler for at least 3 months.

You may not qualify if:

  • pre-terminal/terminal stage of any disease,
  • uncooperative patient,
  • significant limitation of mobility or cognitive functions.
  • HEALTHCARE PROFESSIONALS
  • signed informed consent,
  • completed education in medicine, pharmacy, or nursing,
  • more than one year of working experience,
  • care for patients taking inhaled therapy for BA/COPD.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University Hospital Hradec Králové

Hradec Králové, 500 05, Czechia

RECRUITING

Related Links

MeSH Terms

Conditions

Pulmonary Disease, Chronic ObstructiveAsthma

Interventions

Educational Status

Condition Hierarchy (Ancestors)

Lung Diseases, ObstructiveLung DiseasesRespiratory Tract DiseasesChronic DiseaseDisease AttributesPathologic ProcessesPathological Conditions, Signs and SymptomsBronchial DiseasesRespiratory HypersensitivityHypersensitivity, ImmediateHypersensitivityImmune System Diseases

Intervention Hierarchy (Ancestors)

Socioeconomic FactorsPopulation Characteristics

Central Study Contacts

Josef Malý, Assoc. Prof. PhD.

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
SUPPORTIVE CARE
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 23, 2025

First Posted

September 19, 2025

Study Start

June 3, 2025

Primary Completion (Estimated)

December 31, 2026

Study Completion (Estimated)

December 31, 2028

Last Updated

September 30, 2025

Record last verified: 2025-07

Locations